Talk Bio

Biohaven's BHV-7000 Ion Channel Drug Fails Phase 2 Trial in Major Depressive Disorder

FDA Rejects Biohaven's Ataxia Drug Vyglxia, Forcing Company to Cut Costs After Second Approval Failure

FDA Delays Decision on Biohaven's Troriluzole for Rare Disease, Plans Advisory Committee Review